lorcaserin

Orexigen Therapeutics (NASDAQ: OREX) was upgraded from Neutral to Overweight with a $10 price target by J.P. Morgan on Thursday following FDA approval of the drug Belviq (lorcaserin). Arena Pharmaceuticals (NASDAQ: ARNA) scored a big hit this week after this decision to approve the obesity drug...

Dear Vivus (NASDAQ: VVUS) investors: You are paying $2.5 billion for a company with zero profits in a market space valued at only $3.5 billion annually. Yes, the FDA advisory committee recommended Qnexa be granted approval in a 20-to-2 vote, but remember that Provenge had a unanimous safety vote...

Hapoalim Securities analyst Jon LeCroy reiterated his Buy rating for shares of Arena Pharmaceuticals Inc (Nasdaq: ARNA), with a price target of $6 per share. LeCroy said that Arena Pharmaceuticals (ARNA) presented two pooled analyses at the 2010 ADA meeting that showed that the company's lorcaserin...